Literature DB >> 21649472

Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy.

Akira Miyauchi1, Takumi Kudo, Akihiro Miya, Kaoru Kobayashi, Yasuhiro Ito, Yuuki Takamura, Takuya Higashiyama, Mitsuhiro Fukushima, Minoru Kihara, Hiroyuki Inoue, Chisato Tomoda, Tomonori Yabuta, Hiroo Masuoka.   

Abstract

BACKGROUND: Detectable serum thyroglobulin (Tg) in patients with papillary thyroid carcinoma (PTC) after total thyroidectomy implies unsuccessful surgery, indicating a high risk of recurrence. Serum Tg kinetics in such patients have not been extensively studied. We studied serum Tg kinetics in patients with suppressed serum thyrotropin levels and undetectable anti-Tg antibody to minimize the effects of these factors on Tg values, and evaluated the relationship of prognosis to the serum Tg doubling-time.
METHODS: Between January 1998 and December 2004, 1515 patients with PTC underwent total thyroidectomy in Kuma Hospital. After excluding patients with other thyroid cancers and those positive tests for anti-Tg antibody, there were 426 patients with 4 or more serum Tg measurements at a time that serum thyrotropin concentrations were <0.1 mIU/L. These patients were selected for the present retrospective study. Tg doubling-time was computed using Tg values measured during routine follow-up. Patients were followed for a mean of 88.1 months and a median of 86.7 months.
RESULTS: Of the 426 patients, 137 patients had 4 or more measurements that revealed detectable Tg in serum Tg. The Tg doubling-time (DT), calculated using all available data, varied widely, and were grouped into those that were <1 year (17 patients), those that were 1-3 years (21 patients), and those that were ≥ 3 years (30 patients), as well as those with a negative value due to decrease in serum Tg (69 patients). There were also 88 patients who had three or fewer serum Tg measurements that showed detectable Tg levels, as well as 201 patients in whom serum Tg measurements were below the lower limit of detection. In the group of patients with a Tg-DT of <1 year the cause specific survival at 10 years was 50%, and in the group with a Tg-DT of 1-3 years it was 95%. In all other groups it was 100%. Many classical prognostic factors (TNM stage, age, and gender) as well as the Tg-DT were significant indicators of survival by univariate analysis, but Tg-DT remained the only independent predictor by multivariate analysis. Tg-DT was also the only independent predictor of distant metastases and loco-regional recurrence on multivariate analysis. Tg-DT calculated using only the first four data [Tg-DT (first four data)] was also the only independent predictor of survival, distant metastases, and loco-regional recurrence on multivariate analysis.
CONCLUSIONS: Tg-DT (all data or first four data) is a very strong prognostic predictor superior to the classical prognostic factors in patients with PTC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21649472     DOI: 10.1089/thy.2010.0355

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  56 in total

Review 1.  2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer.

Authors:  Laura Fugazzola; Rossella Elisei; Dagmar Fuhrer; Barbara Jarzab; Sophie Leboulleux; Kate Newbold; Jan Smit
Journal:  Eur Thyroid J       Date:  2019-08-28

Review 2.  Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Gary L Francis; Steven G Waguespack; Andrew J Bauer; Peter Angelos; Salvatore Benvenga; Janete M Cerutti; Catherine A Dinauer; Jill Hamilton; Ian D Hay; Markus Luster; Marguerite T Parisi; Marianna Rachmiel; Geoffrey B Thompson; Shunichi Yamashita
Journal:  Thyroid       Date:  2015-07       Impact factor: 6.568

3.  Letter to the Editor: Reply.

Authors:  Yasuhiro Ito; Akira Miyauchi; Mitsuyoshi Hirokawa
Journal:  World J Surg       Date:  2017-10       Impact factor: 3.352

Review 4.  Advances in the follow-up of differentiated or medullary thyroid cancer.

Authors:  Rossella Elisei; Aldo Pinchera
Journal:  Nat Rev Endocrinol       Date:  2012-04-03       Impact factor: 43.330

5.  Detection and Prognostic Significance of Circulating Tumor Cells in Patients With Metastatic Thyroid Cancer.

Authors:  Jian Yu Xu; Beverly Handy; Christina L Michaelis; Steven G Waguespack; Mimi I Hu; Naifa Busaidy; Camilo Jimenez; Maria E Cabanillas; Herbert A Fritsche; Gilbert J Cote; Steven I Sherman
Journal:  J Clin Endocrinol Metab       Date:  2016-08-30       Impact factor: 5.958

6.  Biochemical persistence in thyroid cancer: is there anything to worry about?

Authors:  Fabián Pitoia; Pitoia Fabián; Erika Abelleira; Abelleira Erika; Hernán Tala; Tala Hernán; Fernanda Bueno; Bueno Fernanda; Carolina Urciuoli; Urciuoli Carolina; Graciela Cross; Cross Graciela
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

7.  Sorafenib and Lenvatinib Treatment for Metastasis/Recurrence of Radioactive Iodine-refractory Differentiated Thyroid Carcinoma.

Authors:  Yasuhiro Ito; Naoyoshi Onoda; Takumi Kudo; Hiroo Masuoka; Takuya Higashiyama; Minoru Kihara; Akihiro Miya; Akira Miyauchi
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

8.  Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Differentiated Thyroid Carcinoma Having Distant Metastasis: A Comparison With Thyroglobulin-doubling Rate and Tumor Volume-doubling Rate.

Authors:  Yasuhiro Ito; Naoyoshi Onoda; Minoru Kihara; Akihiro Miya; Akira Miyauchi
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

Review 9.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

10.  Prolongation of tumour volume doubling time (midDT) is associated with improvement in disease-specific survival in patients with rapidly progressive radioactive iodine refractory differentiated thyroid cancer selected for molecular targeted therapy.

Authors:  Mona M Sabra; Eric Sherman; Robert Michael Tuttle
Journal:  Clin Endocrinol (Oxf)       Date:  2019-02-21       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.